Skip to main content
Top
Published in: International Journal of Pediatric Endocrinology 1/2014

Open Access 01-12-2014 | Research

Proteomic analysis allows for early detection of potential markers of metabolic impairment in very young obese children

Authors: Gabriel Á Martos-Moreno, Lucila Sackmann-Sala, Vicente Barrios, Darlene E Berrymann, Shigeru Okada, Jesús Argente, John J Kopchick

Published in: International Journal of Pediatric Endocrinology | Issue 1/2014

Login to get access

Abstract

Background

Early diagnosis of initial metabolic derangements in young obese children could influence their management; however, this impairment is frequently not overt, but subtle and undetectable by routinely used clinical assays. Our aim was to evaluate the ability of serum proteomic analysis to detect these incipient metabolic alterations in comparison to standard clinical methods and to identify new candidate biomarkers.

Methods

A cross-sectional study of fasting serum samples from twenty-two prepubertal, Caucasian obese (OB; 9.22 ± 1.93 years; 3.43 ± 1.08 BMI-SDS) and twenty-one lean controls (C; 8.50 ± 1.98 years; -0.48 ± 0.81 BMI-SDS) and a prospective study of fasting serum samples from twenty prepubertal, Caucasian obese children (11 insulin resistant [IR]) before (4.77 ± 1.30 BMI-SDS) and after weight reduction (2.57 ± 1.29 BMI-SDS) by conservative treatment in a reference hospital (Pros-OB) was performed. Proteomic analysis (two-dimension-eletrophoresis + mass spectrometry analysis) of serum and comparative evaluation of the sensitivity of routinely used assays in the clinics to detect the observed differences in protein expression level, as well as their relationship with anthropometric features, insulin resistance indexes, lipid profile and adipokine levels were carried out.

Results

Study of the intensity data from proteomic analysis showed a decrease of several isoforms of apolipoprotein-A1, apo-J/clusterin, vitamin D binding protein, transthyretin in OB vs. C, with some changes in these proteins being enhanced by IR and partially reversed after weight loss. Expression of low molecular weight isoforms of haptoglobin was increased in OB, enhanced in IR and again decreased after weight loss, being positively correlated with serum interleukin-6 and NAMPT/visfatin levels. After statistical correction for multiple comparisons, significance remained for a single isoform of low MW haptoglobin (OB vs. C and IR vs. non-IR) and Apo A1 (IR vs. non-IR). Assays routinely used in the clinical setting (ELISA/kinetic nephelometry), only partially confirmed the changes observed by proteomic analysis (ApoA1 and haptoglobin).

Conclusion

Proteomic analysis can allow for the identification of potential new candidate biomarkers as a complement to routinely used assays to detect initial changes in serum markers of inflammation and lipid metabolism impairment in young obese children.
Appendix
Available only for authorised users
Literature
1.
go back to reference Beilin L, Huang RC: Childhood obesity, hypertension, the metabolic syndrome and adult cardiovascular disease. Clin Exp Pharmacol Physiol. 2008, 35: 409-411. 10.1111/j.1440-1681.2008.04887.x.CrossRefPubMed Beilin L, Huang RC: Childhood obesity, hypertension, the metabolic syndrome and adult cardiovascular disease. Clin Exp Pharmacol Physiol. 2008, 35: 409-411. 10.1111/j.1440-1681.2008.04887.x.CrossRefPubMed
2.
go back to reference Camhi SM, Katzmarzyk PT, Broyles S, Srinivasan SR, Chen W, Bouchard C, Berenson GS: Predicting adult body mass index-specific metabolic risk from childhood. Metab Syndr Relat Disord. 2010, 8: 165-172. 10.1089/met.2009.0063.CrossRefPubMed Camhi SM, Katzmarzyk PT, Broyles S, Srinivasan SR, Chen W, Bouchard C, Berenson GS: Predicting adult body mass index-specific metabolic risk from childhood. Metab Syndr Relat Disord. 2010, 8: 165-172. 10.1089/met.2009.0063.CrossRefPubMed
3.
go back to reference Mikhail N: The metabolic syndrome: insulin resistance. Curr Hypertens Rep. 2009, 11: 156-158. 10.1007/s11906-009-0027-4.CrossRefPubMed Mikhail N: The metabolic syndrome: insulin resistance. Curr Hypertens Rep. 2009, 11: 156-158. 10.1007/s11906-009-0027-4.CrossRefPubMed
4.
go back to reference Martos-Moreno GÁ, Barrios V, Chowen JA, Argente J: Adipokines in childhood obesity. Vitamins & Hormones: “Obesity”. Edited by: Litwack G. 2013, Burlington: Academic Press, 107-142. Martos-Moreno GÁ, Barrios V, Chowen JA, Argente J: Adipokines in childhood obesity. Vitamins & Hormones: “Obesity”. Edited by: Litwack G. 2013, Burlington: Academic Press, 107-142.
5.
go back to reference Haider DG, Holzer G, Schaller G, Weghuber D, Widhalm K, Wagner O, Kapiotis S, Wolzt M: The adipokine visfatin is markedly elevated in obese children. J Pediatr Gastroenterol Nutr. 2006, 43: 548-549. 10.1097/01.mpg.0000235749.50820.b3.CrossRefPubMed Haider DG, Holzer G, Schaller G, Weghuber D, Widhalm K, Wagner O, Kapiotis S, Wolzt M: The adipokine visfatin is markedly elevated in obese children. J Pediatr Gastroenterol Nutr. 2006, 43: 548-549. 10.1097/01.mpg.0000235749.50820.b3.CrossRefPubMed
6.
go back to reference Martos-Moreno GÁ, Barrios V, Martínez G, Hawkins F, Argente J: Effect of weight loss on high-molecular weight adiponectin in obese children. Obesity (Silver Spring). 2010, 18: 2288-2294. 10.1038/oby.2010.68.CrossRef Martos-Moreno GÁ, Barrios V, Martínez G, Hawkins F, Argente J: Effect of weight loss on high-molecular weight adiponectin in obese children. Obesity (Silver Spring). 2010, 18: 2288-2294. 10.1038/oby.2010.68.CrossRef
7.
go back to reference Martos-Moreno GA, Kratzsch J, Körner A, Barrios V, Hawkins F, Kiess W, Argente J: Serum visfatin and vaspin levels in prepubertal children: effect of obesity and weight loss after behavior modifications on their secretion and relationship with glucose metabolism. Int J Obes (Lond). 2011, 35: 1355-1362. 10.1038/ijo.2010.280.CrossRef Martos-Moreno GA, Kratzsch J, Körner A, Barrios V, Hawkins F, Kiess W, Argente J: Serum visfatin and vaspin levels in prepubertal children: effect of obesity and weight loss after behavior modifications on their secretion and relationship with glucose metabolism. Int J Obes (Lond). 2011, 35: 1355-1362. 10.1038/ijo.2010.280.CrossRef
9.
go back to reference Ding J, List EO, Okada S, Kopchick JJ: Perspective: proteomic approach to detect biomarkers of human growth hormone. Growth Horm IGF Res. 2009, 19: 399-407. 10.1016/j.ghir.2009.04.018.PubMedCentralCrossRefPubMed Ding J, List EO, Okada S, Kopchick JJ: Perspective: proteomic approach to detect biomarkers of human growth hormone. Growth Horm IGF Res. 2009, 19: 399-407. 10.1016/j.ghir.2009.04.018.PubMedCentralCrossRefPubMed
10.
go back to reference Ding J, Okada S, Jørgensen JO, Kopchick JJ: Novel serum protein biomarkers indicative of growth hormone doping in healthy human subjects. Proteomics. 2011, 11: 3565-3571. 10.1002/pmic.201100077.PubMedCentralCrossRefPubMed Ding J, Okada S, Jørgensen JO, Kopchick JJ: Novel serum protein biomarkers indicative of growth hormone doping in healthy human subjects. Proteomics. 2011, 11: 3565-3571. 10.1002/pmic.201100077.PubMedCentralCrossRefPubMed
11.
go back to reference Sackmann-Sala L, Ding J, Frohman LA, Kopchick JJ: Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth Horm IGF Res. 2009, 19: 471-477. 10.1016/j.ghir.2009.03.001.PubMedCentralCrossRefPubMed Sackmann-Sala L, Ding J, Frohman LA, Kopchick JJ: Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth Horm IGF Res. 2009, 19: 471-477. 10.1016/j.ghir.2009.03.001.PubMedCentralCrossRefPubMed
12.
go back to reference Cruz-Topete D, Jorgensen JO, Christensen B, Sackmann-Sala L, Krusenstjerna-Hafstrøm T, Jara A, Okada S, Kopchick JJ: Identification of new biomarkers of low-dose GH replacement therapy in GH-deficient patients. J Clin Endocrinol Metab. 2011, 96: 2089-2097. 10.1210/jc.2011-0197.PubMedCentralCrossRefPubMed Cruz-Topete D, Jorgensen JO, Christensen B, Sackmann-Sala L, Krusenstjerna-Hafstrøm T, Jara A, Okada S, Kopchick JJ: Identification of new biomarkers of low-dose GH replacement therapy in GH-deficient patients. J Clin Endocrinol Metab. 2011, 96: 2089-2097. 10.1210/jc.2011-0197.PubMedCentralCrossRefPubMed
13.
go back to reference Sobradillo B, Aguirre A, Aresti U, Bilbao A, Fernández-Ramos C, Lizárraga A, Lorenzo H, Madariaga L, Rica I, Ruiz I, Sánchez E, Santamaría C, Serrano JM, Zabala A, Zurimendi B, Hernández M: Curvas y tablas de crecimiento (estudio longitudinal y transversal). Patrones de crecimiento y desarrollo en España. Atlas de gráficas y tablas. Edited by: Orbegozo F. 2004, Madrid: ERGON Sobradillo B, Aguirre A, Aresti U, Bilbao A, Fernández-Ramos C, Lizárraga A, Lorenzo H, Madariaga L, Rica I, Ruiz I, Sánchez E, Santamaría C, Serrano JM, Zabala A, Zurimendi B, Hernández M: Curvas y tablas de crecimiento (estudio longitudinal y transversal). Patrones de crecimiento y desarrollo en España. Atlas de gráficas y tablas. Edited by: Orbegozo F. 2004, Madrid: ERGON
14.
go back to reference Eyzaguirre F, Mericq V: Insulin resistance markers in children. Horm Res. 2009, 71: 65-74. 10.1159/000183894.CrossRefPubMed Eyzaguirre F, Mericq V: Insulin resistance markers in children. Horm Res. 2009, 71: 65-74. 10.1159/000183894.CrossRefPubMed
15.
go back to reference Martos-Moreno GÁ, Sackmann-Sala L, Berryman D, Blome DW, Argente J, Kopchick JJ: The proteome of subcutaneous adipose tissue shows anatomical heterogeneity. An Ped (Barc). 2013, 78: 140-148. 10.1016/j.anpedi.2012.10.010.CrossRef Martos-Moreno GÁ, Sackmann-Sala L, Berryman D, Blome DW, Argente J, Kopchick JJ: The proteome of subcutaneous adipose tissue shows anatomical heterogeneity. An Ped (Barc). 2013, 78: 140-148. 10.1016/j.anpedi.2012.10.010.CrossRef
16.
go back to reference Boes E, Coassin S, Kollerits B, Heid IM, Kronenberg F: Genetic-epidemiological evidence on genes associated with HDL cholesterol levels: a systematic in-depth review. Exp Gerontol. 2009, 44: 136-160. 10.1016/j.exger.2008.11.003.PubMedCentralCrossRefPubMed Boes E, Coassin S, Kollerits B, Heid IM, Kronenberg F: Genetic-epidemiological evidence on genes associated with HDL cholesterol levels: a systematic in-depth review. Exp Gerontol. 2009, 44: 136-160. 10.1016/j.exger.2008.11.003.PubMedCentralCrossRefPubMed
17.
go back to reference Fruchart JC, Ailhaud G: Apolipoprotein A-containing lipoprotein particles: physiological role, quantification, and clinical significance. Clin Chem. 1992, 38: 793-797.PubMed Fruchart JC, Ailhaud G: Apolipoprotein A-containing lipoprotein particles: physiological role, quantification, and clinical significance. Clin Chem. 1992, 38: 793-797.PubMed
18.
go back to reference Duriez P, Fruchart JC: High-density lipoprotein subclasses and apolipoprotein A-I. Clin Chim Acta. 1999, 286: 97-114. 10.1016/S0009-8981(99)00096-0.CrossRefPubMed Duriez P, Fruchart JC: High-density lipoprotein subclasses and apolipoprotein A-I. Clin Chim Acta. 1999, 286: 97-114. 10.1016/S0009-8981(99)00096-0.CrossRefPubMed
19.
go back to reference Ohta T, Saku K, Takata K, Nakamura R, Ikeda Y, Matsuda I: Different effects of subclasses of HDL containing apoA-I but not apoA-II (LpA-I) on cholesterol esterification in plasma and net cholesterol efflux from foam cells. Arterioscler Thromb Vasc Biol. 1995, 15: 956-962. 10.1161/01.ATV.15.7.956.CrossRefPubMed Ohta T, Saku K, Takata K, Nakamura R, Ikeda Y, Matsuda I: Different effects of subclasses of HDL containing apoA-I but not apoA-II (LpA-I) on cholesterol esterification in plasma and net cholesterol efflux from foam cells. Arterioscler Thromb Vasc Biol. 1995, 15: 956-962. 10.1161/01.ATV.15.7.956.CrossRefPubMed
20.
go back to reference Kujiraoka T, Hattori H, Miwa Y, Ishihara M, Ueno T, Ishii J, Tsuji M, Iwasaki T, Sasaguri Y, Fujioka T, Saito S, Tsushima M, Maruyama T, Miller IP, Miller NE, Egashira T: Serum apolipoprotein j in health, coronary heart disease and type 2 diabetes mellitus. J Atheroscler Thromb. 2006, 13: 314-322. 10.5551/jat.13.314.CrossRefPubMed Kujiraoka T, Hattori H, Miwa Y, Ishihara M, Ueno T, Ishii J, Tsuji M, Iwasaki T, Sasaguri Y, Fujioka T, Saito S, Tsushima M, Maruyama T, Miller IP, Miller NE, Egashira T: Serum apolipoprotein j in health, coronary heart disease and type 2 diabetes mellitus. J Atheroscler Thromb. 2006, 13: 314-322. 10.5551/jat.13.314.CrossRefPubMed
21.
go back to reference Falgarone G, Chiocchia G: Chapter 8: Clusterin: a multifacet protein at the crossroad of inflammation and autoimmunity. Adv Cancer Res. 2009, 104: 139-170.CrossRefPubMed Falgarone G, Chiocchia G: Chapter 8: Clusterin: a multifacet protein at the crossroad of inflammation and autoimmunity. Adv Cancer Res. 2009, 104: 139-170.CrossRefPubMed
22.
go back to reference Trougakos IP, Poulakou M, Stathatos M, Chalikia A, Melidonis A, Gonos ES: Serum levels of the senescence biomarker clusterin/apolipoprotein J increase significantly in diabetes type II and during development of coronary heart disease or at myocardial infarction. Exp Gerontol. 2002, 37: 1175-1187. 10.1016/S0531-5565(02)00139-0.CrossRefPubMed Trougakos IP, Poulakou M, Stathatos M, Chalikia A, Melidonis A, Gonos ES: Serum levels of the senescence biomarker clusterin/apolipoprotein J increase significantly in diabetes type II and during development of coronary heart disease or at myocardial infarction. Exp Gerontol. 2002, 37: 1175-1187. 10.1016/S0531-5565(02)00139-0.CrossRefPubMed
23.
go back to reference Krijnen PA, Cillessen SA, Manoe R, Muller A, Visser CA, Meijer CJ, Musters RJ, Hack CE, Aarden LA, Niessen HW: Clusterin: a protective mediator for ischemic cardiomyocytes?. Am J Physiol Heart Circ Physiol. 2005, 289: H2193-H2202. 10.1152/ajpheart.00355.2005.CrossRefPubMed Krijnen PA, Cillessen SA, Manoe R, Muller A, Visser CA, Meijer CJ, Musters RJ, Hack CE, Aarden LA, Niessen HW: Clusterin: a protective mediator for ischemic cardiomyocytes?. Am J Physiol Heart Circ Physiol. 2005, 289: H2193-H2202. 10.1152/ajpheart.00355.2005.CrossRefPubMed
24.
go back to reference van Dijk A, Vermond RA, Krijnen PA, Juffermans LJ, Hahn NE, Makker SP, Aarden LA, Hack E, Spreeuwenberg M, van Rossum BC, Meischl C, Paulus WJ, Van Milligen FJ, Niessen HW: Intravenous clusterin administration reduces myocardial infarct size in rats. Eur J Clin Invest. 2010, 40: 893-902. 10.1111/j.1365-2362.2010.02345.x.CrossRefPubMed van Dijk A, Vermond RA, Krijnen PA, Juffermans LJ, Hahn NE, Makker SP, Aarden LA, Hack E, Spreeuwenberg M, van Rossum BC, Meischl C, Paulus WJ, Van Milligen FJ, Niessen HW: Intravenous clusterin administration reduces myocardial infarct size in rats. Eur J Clin Invest. 2010, 40: 893-902. 10.1111/j.1365-2362.2010.02345.x.CrossRefPubMed
25.
go back to reference Asleh R, Levy AP: In vivo and in vitro studies establishing haptoglobin as a major susceptibility gene for diabetic vascular disease. Vasc Health Risk Manag. 2005, 1: 19-28. 10.2147/vhrm.1.1.19.58930.PubMedCentralCrossRefPubMed Asleh R, Levy AP: In vivo and in vitro studies establishing haptoglobin as a major susceptibility gene for diabetic vascular disease. Vasc Health Risk Manag. 2005, 1: 19-28. 10.2147/vhrm.1.1.19.58930.PubMedCentralCrossRefPubMed
26.
go back to reference Quaye IK: Haptoglobin, inflammation and disease. Trans R Soc Trop Med Hyg. 2008, 102: 735-742. 10.1016/j.trstmh.2008.04.010.CrossRefPubMed Quaye IK: Haptoglobin, inflammation and disease. Trans R Soc Trop Med Hyg. 2008, 102: 735-742. 10.1016/j.trstmh.2008.04.010.CrossRefPubMed
27.
go back to reference Kalmovarin N, Friedrichs WE, O'Brien HV, Linehan LA, Bowman BH, Yang F: Extrahepatic expression of plasma protein genes during inflammation. Inflammation. 1991, 15: 369-379. 10.1007/BF00917353.CrossRefPubMed Kalmovarin N, Friedrichs WE, O'Brien HV, Linehan LA, Bowman BH, Yang F: Extrahepatic expression of plasma protein genes during inflammation. Inflammation. 1991, 15: 369-379. 10.1007/BF00917353.CrossRefPubMed
28.
go back to reference Benedek IH, Blouin RA, McNamara PJ: Serum protein binding and the role of increased alpha 1-acid glycoprotein in moderately obese male subjects. Br J Clin Pharmacol. 1984, 18: 941-946. 10.1111/j.1365-2125.1984.tb02567.x.PubMedCentralCrossRefPubMed Benedek IH, Blouin RA, McNamara PJ: Serum protein binding and the role of increased alpha 1-acid glycoprotein in moderately obese male subjects. Br J Clin Pharmacol. 1984, 18: 941-946. 10.1111/j.1365-2125.1984.tb02567.x.PubMedCentralCrossRefPubMed
29.
go back to reference Galazis N, Afxentiou T, Xenophontos M, Diamanti-Kandarakis E, Atiomo W: Proteomic biomarkers of type 2 diabetes mellitus risk in women with polycystic ovary syndrome. Eur J Endocrinol. 2013, 168: 33-43. 10.1530/EJE-12-0718.CrossRef Galazis N, Afxentiou T, Xenophontos M, Diamanti-Kandarakis E, Atiomo W: Proteomic biomarkers of type 2 diabetes mellitus risk in women with polycystic ovary syndrome. Eur J Endocrinol. 2013, 168: 33-43. 10.1530/EJE-12-0718.CrossRef
30.
go back to reference Frey SK, Spranger J, Henze A, Pfeiffer AF, Schweigert FJ, Raila J: Factors that influence retinol-binding protein 4-transthyretin interaction are not altered in overweight subjects and overweight subjects with type 2 diabetes mellitus. Metabolism. 2009, 58: 1386-1392. 10.1016/j.metabol.2009.05.003.CrossRefPubMed Frey SK, Spranger J, Henze A, Pfeiffer AF, Schweigert FJ, Raila J: Factors that influence retinol-binding protein 4-transthyretin interaction are not altered in overweight subjects and overweight subjects with type 2 diabetes mellitus. Metabolism. 2009, 58: 1386-1392. 10.1016/j.metabol.2009.05.003.CrossRefPubMed
31.
go back to reference Codoñer-Franch P, Tavárez-Alonso S, Simó-Jordá R, Laporta-Martín P, Carratalá-Calvo A, Alonso-Iglesias E: Vitamin D status is linked to biomarkers of oxidative stress, inflammation, and endothelial activation in obese children. J Pediatr. 2012, 161: 848-854. 10.1016/j.jpeds.2012.04.046.CrossRefPubMed Codoñer-Franch P, Tavárez-Alonso S, Simó-Jordá R, Laporta-Martín P, Carratalá-Calvo A, Alonso-Iglesias E: Vitamin D status is linked to biomarkers of oxidative stress, inflammation, and endothelial activation in obese children. J Pediatr. 2012, 161: 848-854. 10.1016/j.jpeds.2012.04.046.CrossRefPubMed
32.
go back to reference Rothman KJ: No adjustments are needed for multiple comparisons. Epidemiology. 1990, 1: 43-46. 10.1097/00001648-199001000-00010.CrossRefPubMed Rothman KJ: No adjustments are needed for multiple comparisons. Epidemiology. 1990, 1: 43-46. 10.1097/00001648-199001000-00010.CrossRefPubMed
Metadata
Title
Proteomic analysis allows for early detection of potential markers of metabolic impairment in very young obese children
Authors
Gabriel Á Martos-Moreno
Lucila Sackmann-Sala
Vicente Barrios
Darlene E Berrymann
Shigeru Okada
Jesús Argente
John J Kopchick
Publication date
01-12-2014
Publisher
BioMed Central
Published in
International Journal of Pediatric Endocrinology / Issue 1/2014
Electronic ISSN: 1687-9856
DOI
https://doi.org/10.1186/1687-9856-2014-9

Other articles of this Issue 1/2014

International Journal of Pediatric Endocrinology 1/2014 Go to the issue